Carrier-Free Self-Assembled Nanomedicines for Promoting Apoptosis and Inhibiting Proliferation in Hepatocellular Carcinoma
Source abstract
Abstract
In order to improve the effectiveness of tumor treatment and reduce the toxic side effects of drugs, we formed carrier-free multifunctional nanoparticles (BI NPs) by noncovalent interaction of berberine hydrochloride and IR780. BI NPs possessed the synergistic effects of promoting apoptosis, inhibiting proliferation and metastasis of tumors, and phototherapeutic treatment. Dispersive and passive targeting ability retention (EPR) effects of BI NPs on tumor sites in vivo could be monitored by fluorescence imaging. In addition, BI NPs exhibited effective reactive oxygen species (ROS) generation and photothermal conversion capabilities, photodynamic therapy (PDT), and photothermal therapy (PTT). Importantly, BI NPs inhibit tumor suppression through the AMPK/PI3K/AKT signaling pathway to inhibit tumor proliferation and metastasis. BI NPs not only have efficient in vivo multimodal therapeutic effects but also have good biosafety and potential clinical applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Medical School, Southeast University, Nanjing 210009, China
Department of Ultrasound, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China
Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China
Funding
National Natural Science Foundation of China · Social Development Project of Jiangsu Province · Preface Leading Technical Basic Research Special Project of Jiangsu Province
References (56)
Show source-provided references
1. 10.1038/s41572-020-00240-310.1038/s41572-020-00240-3 ↗
2. 10.1016/j.jhep.2014.10.03710.1016/j.jhep.2014.10.037 ↗
3. 10.1093/bjs/znab37610.1093/bjs/znab376 ↗
4. 10.1111/liv.1505210.1111/liv.15052 ↗
5. 10.1016/S0140-6736(22)01200-410.1016/S0140-6736(22)01200-4 ↗
6. 10.1016/S0140-6736(23)00961-310.1016/S0140-6736(23)00961-3 ↗
7. 10.1200/JCO.22.0062010.1200/JCO.22.00620 ↗
8. 10.1016/j.jhep.2011.07.03110.1016/j.jhep.2011.07.031 ↗
9. 10.1002/ptr.569310.1002/ptr.5693 ↗
10. 10.1016/j.jacc.2018.04.04010.1016/j.jacc.2018.04.040 ↗
11. 10.1038/nrendo.2016.21010.1038/nrendo.2016.210 ↗
12. 10.3390/ph1601004210.3390/ph16010042 ↗
13. 10.1186/1476-4598-10-3910.1186/1476-4598-10-39 ↗
14. 10.3892/or.2013.254310.3892/or.2013.2543 ↗
15. 10.1126/science.abn172510.1126/science.abn1725 ↗
16. 10.1038/s41580-022-00547-x10.1038/s41580-022-00547-x ↗
17. 10.1038/s41580-022-00486-710.1038/s41580-022-00486-7 ↗
18. 10.1002/jcb.2286910.1002/jcb.22869 ↗
19. 10.3892/mmr.2013.150610.3892/mmr.2013.1506 ↗
20. 10.1038/s41568-019-0216-710.1038/s41568-019-0216-7 ↗
21. 10.1038/nrclinonc.2018.2810.1038/nrclinonc.2018.28 ↗
22. 10.3892/ol.2017.652610.3892/ol.2017.6526 ↗
23. 10.3892/etm.2015.263710.3892/etm.2015.2637 ↗
24. 10.1002/ddr.2206110.1002/ddr.22061 ↗
25. 10.3390/ph1510119910.3390/ph15101199 ↗
26. 10.1016/j.biotechadv.2019.04.00410.1016/j.biotechadv.2019.04.004 ↗
27. 10.18632/oncotarget.1672310.18632/oncotarget.16723 ↗
28. 10.1038/s41565-021-00950-z10.1038/s41565-021-00950-z ↗
29. 10.1016/j.cell.2023.03.00610.1016/j.cell.2023.03.006 ↗
30. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
31. 10.1186/s12951-022-01310-210.1186/s12951-022-01310-2 ↗
32. 10.1039/C8CS00618K10.1039/C8CS00618K ↗
33. 10.3322/caac.2011410.3322/caac.20114 ↗
34. 10.1021/acs.chemrev.0c0066310.1021/acs.chemrev.0c00663 ↗
35. 10.1016/j.jconrel.2020.06.03210.1016/j.jconrel.2020.06.032 ↗
36. 10.1039/D1CS00056J10.1039/D1CS00056J ↗
37. 10.1016/j.biomaterials.2013.05.07110.1016/j.biomaterials.2013.05.071 ↗
38. 10.1016/j.ijpharm.2018.03.02010.1016/j.ijpharm.2018.03.020 ↗
39. 10.1021/acsami.8b2196810.1021/acsami.8b21968 ↗
40. 10.1016/j.biomaterials.2019.11958010.1016/j.biomaterials.2019.119580 ↗
41. 10.1002/advs.20180004910.1002/advs.201800049 ↗
42. 10.1002/adma.20230298510.1002/adma.202302985 ↗
43. 10.1002/adma.20230383110.1002/adma.202303831 ↗
44. 10.1002/adma.20230178410.1002/adma.202301784 ↗
45. 10.1002/adma.20230135210.1002/adma.202301352 ↗
46. 10.1021/am502541g10.1021/am502541g ↗
47. 10.1016/j.jhazmat.2020.12207510.1016/j.jhazmat.2020.122075 ↗
48. 10.1021/acssuschemeng.8b0151110.1021/acssuschemeng.8b01511 ↗
49. 10.1016/j.cej.2019.12316910.1016/j.cej.2019.123169 ↗
50. 10.1021/ja105059g10.1021/ja105059g ↗
51. 10.1021/acsami.6b0241610.1021/acsami.6b02416 ↗
52. 10.1016/j.ccr.2024.21567210.1016/j.ccr.2024.215672 ↗
53. 10.1021/acs.langmuir.0c0252110.1021/acs.langmuir.0c02521 ↗
54. 10.1021/acs.chemrev.0c0077910.1021/acs.chemrev.0c00779 ↗
55. 10.7150/thno.3064010.7150/thno.30640 ↗
56. 10.1002/jcb.2238410.1002/jcb.22384 ↗